Table 4.
Final diagnosis
| TM-positive group (N = 76) |
TM-negative group (N = 59) |
|||||
|---|---|---|---|---|---|---|
| Total (N = 135) |
Cancer (N = 41) |
No cancer (N = 35) |
Cancer (N = 9) |
No cancer (N = 50) |
p* | |
| Cancer, n/N (%) | 50/135 (37.0) | 41/76 (53.9) | 0/76 | 9/59 (15.3) | 0/59 | < 1.10 -4 |
| Organ, n/N (%) | ||||||
| Hematologic cancer | 12/50 (24.0) | 9/41 (22.0) | 3/9 (33.3) | 0.79 | ||
| Upper digestive tract# | 3/50 (6.0) | 2/41 (4.9) | 1/9 (11.1) | NA | ||
| Lower digestive tract§ | 5/50 (10.0) | 3/41 (7.3) | 2/9 (22.2) | NA | ||
| Liver | 2 /50 (4.0) | 2/41 (5.0) | 0/9 | NA | ||
| Pancreas | 3/50 (6.0) | 3/41 (7.3) | 0/9 | NA | ||
| Biliary tract | 3/50 (6.0) | 3/41 (7.3) | 0/9 | NA | ||
| Lung | 7/50 (14.0) | 6/41 (14.6) | 1/9 (11.1) | NA | ||
| Breast | 3/50 (6.0) | 3/41 (7.3) | 0/9 | NA | ||
| Ovary | 3/50 (6.0) | 3/41 (7.3) | 1/9 (11.1) | NA | ||
| Prostate | 2/50 (4.0) | 1/41 (2.4) | 1/9 (11.1) | NA | ||
| Urinary tract | 2/50 (4.0) | 1/41 (2.4) | 0/9 | NA | ||
| Central nervous system | 1/50 (2.0) | 1/41 (2.4) | 0/9 | NA | ||
| Not known or uncertain | 4 /50 (8.0) | 4/41 (9.8) | 0/9 | NA | ||
| Histology, n/N(%) | ||||||
| Epithelial tumor | 32/47 (68.1) | 26/38(68.4) | 6/9 (66.67) | 1 | ||
| Nonepithelial tumor | 15/47(31.9) | 12/38 (31.6) | 3/9 (33.33) | 1 | ||
| - Neuroendocrine tumor | 2/15 (12.5) | 2/12 (16.7) | 0/9 | NA | ||
| - MPS | 9/15 (56.3) | 6/12 (50.0) | 3/3 (100) | 0.043 | ||
| - LPS | 1/15 (6.3) | 1/12 (8.3) | 0/3 | NA | ||
| - MDS | 2/15 (12.5) | 2/12 (16.7) | 0/3 | NA | ||
| - GIST | 1/15 (6.3) | 1/12 (8.3) | 0/3 | NA | ||
| Stage, n/N(%) | ||||||
| I | 5/42 (11.9) | 3/33 (9.1) | 2/9 (22.2) | NA | ||
| II | 4/42 (9.5) | 2/33 (6.1) | 2/9 (22.2) | NA | ||
| III | 2/42(4.8) | 2/33 (6.1) | 0/9 | NA | ||
| IV | 31/42 (73.8) | 26/33 (78.8) | 5/9 (55.6) | 0.37 | ||
| Benign disease, n/N(%) | 81/135 (60.0) | 35/76 (46.0) | 46/59(78.0) | < 0.001 | ||
| Infection | 14/81 (17.3) | 5/35 (14.3) | 9/46 (19.6) | 0.74 | ||
| AID | 45/81 (55.6) | 22/35 (62.8) | 23/46 (50) | 0.35 | ||
| Endocrinopathy | 2/81(2.5) | 1/35 (2.9) | 1/46 (2.2) | NA | ||
| Digestive tract disorder | 7/81 (8.6) | 2/35 (5.7) | 5/46 (10.9) | NA | ||
| Neurologic disorder | 3/81 (3.7) | 1/35 (2.9) | 2/46 (4.3) | NA | ||
| Crystal arthropathy | 2/81 (2.5) | 2/35 (5.7) | 0/46 | NA | ||
| Adverse drug reactions | 2/81(2.5) | 0/35 | 2/46 (4.3) | NA | ||
| Other | 6/81 (7.4) | 2/35 (5.7) | 4/46 (8.7) | NA | ||
| No final diagnosis, n/N(%) | 4/135 (3.0) | 0/35 | 4/50 (8.0) | NA | ||
Legends AID: autoimmune disease, GIST: gastrointestinal stromal tumor, LPS: lymphoproliferative syndrome, MDS: myelodysplasia syndrome, MPS: myeloproliferative syndrome, NA: not applicable
* TM-positive patients vs. TM-negative patients